ASH, European Hematology Association name training program participants

ASH and the European Hematology Association selected 20 early-career hematologists to participate in the 2016 Translational Research Training in Hematology joint program.

The program offers a yearlong training and mentoring experience designed to help junior scientists build successful careers in translational hematologic research. Under the guidance of international leaders, participants learn the fundamental principles related to translational research, including developing a hypothesis and applying the scientific method to test that hypothesis in the laboratory.

Charles S. Abrams

“Talented researchers emerge from the [training] program with the knowledge and professional network that will position them for success as they continue to grow their careers in the important discipline of translational research,” ASH President Charles S. Abrams, MD, chief of nonmalignant hematology, vice chair for research and chief scientific officer at University of Pennsylvania School of Medicine, said in a press release. “We thank our partners and donors for contributing to the success of these 20 program participants who we have no doubt will make important discoveries that will change how we treat blood disorders.”

This year’s participants are Gregory Behbehani, MD, PhD, of The Ohio State University; Melinda Biernacki, MD, of University of Washington and Fred Hutchinson Cancer Research Center; Chun-Wei Chen, PhD, of Memorial Sloan Kettering Cancer Center; Karen De Ceunynck, PhD, of Beth Israel Deaconess Medical Center; Diana Passaro, PhD, of The Francis Crick Institute in London; Chun Yew Fong, MD, of Peter MacCallum Cancer Centre in Australia; Alexander Höllein, MD, of Technical University of Munich in Germany; Raphael Itzykson, MD, PhD, of Hôpital Saint-Louis and Université Paris Diderot; Robert Kridel, MD, of BC Cancer Agency in British Columbia, Canada; Kate Markey, MBBS, PhD, of The Royal Brisbane and Women’s Hospital in Australia; Mark Murakami, MD, of Dana-Farber Cancer Institute; Jyoti Nangalia, MBBChir, of University of Cambridge in England; Elodie Pronier, PhD, of Memorial Sloan Kettering Cancer Center; Suthesh Sivapalaratnam, MD, of University of Cambridge in England; Elliot Stieglitz, MD, of The University of California, San Francisco; Elisa ten Hacken, PhD, of The University of Texas MD Anderson Cancer Center; Iris Uras, PhD, of Institute of Pharmacology and Toxicology at University of Veterinary Medicine in Vienna; Mireya Paulina Velasquez, MD, of Baylor College of Medicine; Janghee Woo, MD, PhD, of University of Washington and Fred Hutchinson Cancer Research Center; and Bas Wouters, MD, PhD, of Erasmus Medical Center in Rotterdam, the Netherlands.